Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S.

New Post Public Reply Private Reply Replies (1) Message Board

Feb 22, 2012 at 12:12 PM

Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) critical ailment formulations, is excited to announce the appointment of world renowned Cannabis Cultivator Bret Bogue as Director of Horticulture for the company. Mr. Bogue is a valuable addition to the company, with decades of experience growing cannabis for medical purposes.

Mr. Bogue will play a key role in the development and maintenance of all horticulture operations for the company while developing specific strains for mass production for the company’s growing standards and critical ailment formulations developed by the company. Mr. Bogue will be a part of the lead development team for plants and strains to be used to develop these medical cannabis formulations and products for Cannabis Science.

Being a critical cancer patient himself, Mr. Bogue was diagnosed with a very rare form of melanoma in 1995. Mr. Bogue stated, "I became very ill and was looking for an alternative medication for my illness, so I realized then that I needed to create Apothecary™ Genetics to provide an alternative treatment solution in the early 90s. Through my world travels, I have been able to find ‘land race strains’ and breed them with hybrids to create World Class medical cannabis.”

Bret and Apothecary went on to become the first American-based seed company to win the coveted Cannabis Cup in Amsterdam in 2007, and has won many other international and national awards for his medical cannabis developments. Having over 20 years of experience creating unique medical strains of cannabis, such as Grape Ape aka GDP, Kaia Kush, Sour Grapes, Old School Jams, and Goo, just to name a few, has put Bret and Apothecary Genetics on the world map as one of the top leaders in medical cannabis development.

Mr. Bogue concludes with, “ I was able to cure my melanoma by using medical cannabis in combination with standard radiation treatment. I am the living proof that medical cannabis kills cancer cells.”

As well, Bret is embarking on some exciting new projects such as a documentary with television giant A&E. Two pilots have already been filmed and sent to New York for review and approvals. The documentary will show real patients who are having real, positive results with medical cannabis. These patients include seniors from a senior citizens’ community in California. Viewers will see the reality of the medication’s benefits, as well as the emotions that come into play when someone is chronically ill.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

http://www.cannabisscience.com/

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Democratic Congress: Tax, Tariff, Regulation Shifts

Shifting Legislative Sands for Business Giddy up, folks! The political tectonic plates just shifted with Democrats grabbing the reins of Congress. For businesses trying to keep their heads above water or score a victory lap, this change could mean adjusting to new winds blowing from Capitol Hill. What could this Democratic majority spell out for taxes, tariffs, and...

Tata Power Faces Enforcement Order for $650M Debt

Tata's Troubles Escalate Grab a cup of coffee, folks, because this is one rollercoaster of a story that every investor needs to have on their radar. We're talking about Singapore courts coming down on Tata Power like a freight train, with enforcement orders that feel like a page out of a high-stakes drama. The Gavel Drops: What's Happening? The court in Singapore has...

TEN Holdings' Q3: Cost Cuts Fuel Revenue Ambitions

TEN Holdings Eyes the Future While Cleaning House If there’s one thing that catches the eye about TEN Holdings' Q3 2026 results, it’s the laser-focused cleanup of their balance sheet. They’ve slashed liabilities by 74%, up from $7.7 million at the arse end of last year to just over $2 million now. They did that by making some hard moves, hacking away at operating...

Tenax Sued: Investors Face Class Action Over TNX-103

What Tenax Investors Need to Know Alright, folks, time to pull up a chair and pay attention to what's brewing with Tenax Therapeutics—yeah, we're talking NASDAQ: TENX. The company's head is spinning as it's caught up in a securities class action lawsuit. What's the fuss? The fine print here accuses Tenax of misleading investors about the effectiveness of their product,...

Elanco Surges with Solid Q3, Raises 2026 Forecast

Strong Q3 Performance Ignites Elanco's Growth Now here's a headline: Elanco's numbers are charging like a bull on steroids. Revenue surged 11% year-over-year to hit a cool $1.265 billion, showing off a 9% organic constant currency growth. And why should we, the investors, care? Because they've adjusted their EBITDA margin upwards to 19.5%, an impressive 2% boost from the...

Habitat for Humanity AZ's Unique Gala: An Overview

Mark Your Calendars: A Night to Celebrate Listen up, Central Arizona, because I'm giving you the lowdown on Habitat for Humanity Central Arizona's big night out. "Blueprints & Blue Jeans" - it's the gala that's ditching the formalities for some good old-fashioned community fun, but with a seriously important mission at its heart. Mark your calendars for Friday, March 5,...

ACR Poker's $20M OSS Leads High-Stakes Weekend

Sunday Showdown at ACR: A Massive Poker Feast Kicking off the action on November 8, ACR Poker brings its Online Super Series (OSS) into the spotlight, and listen up—there's a cool $20 million spread on the table through November 24. What's got people really tuned in, though, is the mix of big stakes, high tension events, and a shot at paradise over in the Bahamas....

Kuaishou Prepares for Q3 Financial Reveals—November 19

We're watching the countdown to November 19, 2026, when Kuaishou Technology plans to spill the beans on its third-quarter earnings. Now, the clock's ticking not just in Beijing but across the financial landscape, as investors everywhere hold their breaths, hoping for some juicy financial insights from this colossal social platform. It's a heavyweight showdown any stock...

Andersen's Window Revamp: Addressing Demand Surge

Portfolio Boost: Adapting to Market Needs If you're sniffing around the windows business, there's a fresh breeze of innovation blowing from Andersen. They're not just sitting around drumming their fingers—they're rolling up their sleeves and fine-tuning their offerings. With half of homeowners swinging a hammer on renovations last year, the company sees an opportunity...

McKinley Irvin Earns Top 2027 Rankings in Family Law

A Legal Eagle Soars High in 2027 Oh, the legal world can be as cutthroat as the stock market some days, especially when you're gunning for those top-tier rankings. This year, McKinley Irvin has managed to ruffle a few feathers in the Pacific Northwest, claiming top honors in the 2027 Best Law Firms rankings. And let me tell you, this wasn’t just handed to them on a...